That is outstanding news, still can't get my head around why ISCO trades so low compared to it's peers, but I guess I just have to put my money where my mouth is, which I have been doing for a while now.

GLTA.

A.H

OMG again! please come up with something new, it is getting really tired and repetitive now.

And yes we are all aware of the issues you mention every day, nothing new under the sun there, however as the share price increases the dilution will be less.

they still have increasing revenues and some bloody outstanding patents behind them. try and focus on that for a change

GLTA.

A.H

A short breather and now 260k left, really happy to see the bullish mood here.

GLTA.

A.H

Well it is definitely on the move now, chipping away nicely at the 540k that was for sale at 0.10, now only 340k left.

GLTA.

A.H

Wow 255000 on the bid at 0.094, some big buyers at the moment, great news although I am disappointed that I had to go to their web site to find it, it isn't on Bigcharts, Ihub or even my broker Charles Schwab, they really should make sure that their news is spread as far as possible, otherwise it will have limited effect if nobody sees it.

Anyways it does look like the investors did see it today as the buying pressure is very good.

GLTA.

A.H

if the CEO keeps on buying as he has just done, then I am fine with it, I do however still believe they should put the IND on the back burner for now, and concentrate on their two revenue generating avenues.

become profitable first and then worry about the IND, that would keep dilution to a min.

GLTA.

A.H

You really should, I have been taking anatabloc for about two years now.

GLTY.

A.H

Hi TFG.

So sorry to hear about your Sons asthma, please have a look at the company listed below, this is Rock creek pharmaceuticals, which produces Anatabloc an anti inflammatory compound, which many on that board has testified works great for asthma, I don't need to tell you to do your own research first though.

I am glad to hear that he is doing a lot better.

http://investorshub.advfn.com/Rock-Creek-Pharmaceuticals-Inc-RCPI-13224/

GLTA.

A.H

The volume is not so heavy today, so you could be right, might this finally be the turning point after days of hammering. Just can't get my head around the continuing pounding even after great news released, this latest news could indeed turn interesting even if it might be a year down the line.

In my view ISCO should put the Parkinson IND on the back burner for now, reduce cost and focus on their two revenue streams in order to become profitable as soon as possible, this would IMHO remove the fear of massive dilution and raise the share price significantly once the first profitable quarter is achieved.

Then go to the market and raise significant finances to complete at least the first stage Parkinson trial.

I would be happy to wait up to a year before raising that financing and progress with the 1st stage trial, this could bring a signed contract in place as well with Rotho which would send ISCO flying and reduce the dilution to a minimum.

Any thoughts?

GLTA.

A.H

it is just disgusting IMHO, and I have seen it so often in these financing deals, as soon as an OTC development company signs the dotted line in any kind of stock conversion financing deal, then you can be sure the stock price will eventually be dragged down into the toilet, just bloody disgusting and makes this European investor serious considering leaving the US markets for good. what really gets me is that jobs comes from small development companies, they are the real driver of jobs growth, Unfortunately too many of these are driven to bankruptcy by all the fraud and manipulation in the OTC market, a damn shame I say.

GLTA.

A.H

Very possible, so much for the anti shorting clause in the contract.

GLTA.

A.H

Couldn't agree more K, sorry can't reply private.

GLTY.

A.H

They are doing their best to drive it below 9 cents, 3.6 mil shares traded so far, I think we are close to the bottom here.

GLTA.

A.H

Wow ISCO is under attack, either that or one or more bigger holders are getting out in a hurry.

To me it looks like a bear raid though IMHO.

will get some more tomorrow if it stays down here, should recover some by Friday if this is an attack, as the traders will cover before the Weekend.

GLTA.

A.H

it definitely took a beating today, added some at 0126, lets see if it recovers over the next few days, either that or it will continue down, it did go to the lowest level in the last year, which is a slight worry for me.

Anyways I expect it to recover as we approach 2nd quarter numbers.

GLTA.

A.H

Thanks Unbias.

That is my understanding as well, so 4th quarter revenue would then be 1735,000 - 277,000 = $1458,000

That is a drop from the $1670,000 in 3rd Quarter revenue of $212,000

GLTA.

A.H

Thanks Karin.

Furthermore it looks like the number was $256000 per the 10K or $277000 per the CC instead of the $300000 I quoted.

Thanks anyway, looking forward to your view of it.

GLTA.

A.H

Does anybody know what this deferred revenue mentioned in the CC is about, it looks like they have deferred revenue of about $300K from Jan 2014 into 4Q 2013, am I wrong in assuming that?

it was asked as a question during the call, and wasn't answered fully, is anybody able to clarify


Part 4 of the CC below.

unidentified Analyst
Yes. I just had a question about the deferred revenue that you’re able to recognize in 2013. What quarter did you recognize that in?

Dr. Simon Craw - Executive Vice President
Thank you. Let me have Jay answer that question. Jay?

Jay Novak - Chief Financial Officer
Sure. The deferred revenue was recognized in the fourth quarter, and historically we had a 30-day lag in recognizing revenue for the Skin Care. This is specific to our Skin Care subsidiary, and that is specifically due to the fact that they have a -- the customers have a 30-day return.

Unidentified Analyst
Okay. I think I understand that. Then my question for you is, what was your revenue in the fourth quarter then both gross and then net of the deferral?

Dr. Simon Craw - Executive Vice President
I believe the deferral…

Jay Novak - Chief Financial Officer
The deferral was about $277,000.

Dr. Simon Craw - Executive Vice President
Right.

Unidentified Analyst
Yes.

Dr. Simon Craw - Executive Vice President
So, it took $277,000…

Jay Novak - Chief Financial Officer
Revenues were about $2.9 million without the deferral, without recognition of the deferrals.

Unidentified Analyst
I was trying to figure out what kind of revenue growth -- you can go back to the past statements, you can quickly, easily identify the revenue growth that’s occurring from quarter-to-quarter also. And I was trying to figure out what kind of revenue growth was occurring in the fourth quarter or sort of natural revenue growth excluding the impact of the deferrals like in (inaudible), just wanted to get a better understanding?

Jay Novak - Chief Financial Officer
Yes. Sure. So, the revenue growth was 47% including the recognition of the deferral, which is obviously slightly inflated, but if you take out the recognition of deferral, it is about 33%, so still a pretty healthy rate.

Unidentified Analyst
Is that from the fourth quarter to the third quarter or is that from year-to-year?

Jay Novak - Chief Financial Officer
It’s year-over-year.

Dr. Simon Craw - Executive Vice President
Yes, year-over-year.

Unidentified Analyst
I guess I was interested in what the growth was from the third quarter to the fourth quarter?

Dr. Simon Craw - Executive Vice President
Okay. Well, can we take the next question, while we look out for that information? We will get back to you on that, Ron.

Unidentified Analyst
Thank you.

Operator

(Operator Instructions). Your next question comes from the line of George [Matal]. Please go ahead.

Unidentified Analyst
Simon, it’s George [Matal].

Dr. Simon Craw - Executive Vice President
Hello George.

Unidentified Analyst
Hello sir. Good to seeing you at the Roth Conference. My question is companies like Stem Cells have received a tremendous grant from California for the research, are we as a company, as International Stem Cell in line for something like that in non-dilutive funding in addition to albeit a great work you're doing?

Dr. Simon Craw - Executive Vice President
That's a good question, George. Thanks for that. The short answer is yes, we continue to apply for grants from various non-funding aides -- from various governmental funding agencies that would provide non-dilutive funding for our research and development. We are in the process of applying for a number of [same] (ph) grants through the California Institute for Regenerative Medicine.

It's fair to say that so far we have been unsuccessful in obtaining those grants; I think one of the keys is to have a very strong academic partner to your research, and over the last year or two, we’ve built some very strong links into the local academic community at Sanford-Burnham for example with the addition of Evans Snyder to our scientific board, and I think through those relationships, we can look forward to potentially being more successful in grant applications.

Unidentified Analyst
Thank you.

Operator

(Operator Instructions). And we have no further questions at this time. You may continue.

Dr. Simon Craw - Executive Vice President
Okay. Let me just cycle back to a question earlier on about the growth in the fourth quarter revenue. Unfortunately, we don't have that data in front of us right now. Is that correct Jay?

Jay Novak - Chief Financial Officer
I have the Q4 data, but I do not have Q3 with me here. So, I can tell you that the Q4 data tells me that Skin Care revenues were about $758,000 for the quarter, for the fourth quarter.

Dr. Simon Craw - Executive Vice President
So Ron, if you’d like to give us a call after this call, we can talk you through it in more detail. If at all, we can refer you to the 10-Q that was published in November and reference the K that we just issued. So with that, I’d like to close the call and thank everyone for joining us this morning on this update. Thank you.


GLTA.

A.H

Does anybody have a link to the transcript for the annual result conference call please. Can't find it on their website

TIA.

A.H

bullshit paint at close LOL, not for much longer though.

GLTA.

A.H

Well for me it is as I have been averaging down, also breaking through the 30 cent would only be a step on the way to dollar range, which will surely come with the announcement of a sale.

GLTA.

A.H

You are welcome, can't post privately any longer.

GLTA.

A.H

4kids.

That was my buy for 23000 shares in the beginning of the day at 0.205 in case you are still tracking.

Looks like JBII is about to take off in a big way, I wont be surprised to see us breaking through 30 cents within the next week.
Can't wait to see what happens when sales of the processors is announced $1-2?

GLTA.

A.H

me too, but most of all I want to invest in whatever company that brings it to the market.

GLTA.

A.H

Thanks for all your postings here, it offers great insight into what has been going on inside the walls of JBII. How confident are you in them selling processor 4 and 5?

Also are you a shareholder here and if so, how long have you been a holder of JBII.

TIA.

A.H

I have to agree too, or hope might be a better word, if not then we are in serious trouble, I just can't get my head around how this company operates and makes decisions, can only hope that this 8K hides more news which is yet to come.

Most crazy investment I have ever been involved in.

GLTA.

A.H

Would you happen to have the name of the documentary please.

GLTA.

A.H

Bought 19000 at 10 cent.

GLTA.

A.H

lets see what it does today, I think an uptrend has begun though, and I am quite exited to see what it will do over the next few weeks, the dilution will become less with the latest financing deal, the higher it goes.

GLTA.

A.H

Me too, I don't believe this is just due to an email campaign by Qualitystocks, volume is increasing quite a lot, and there are many buyers out there to meet demand, yesterdays dump of half a mil shares in the last half hour, were all soaked up, with only a small drop in price, any other day and the stock would have tanked with this many shares being put up for sale.

Anyways patience is key here, as ISCO is going to move greatly at some point this year, I however believe it will be in the next two Months.

GLTA.

A.H

Couldn't agree more, I think it is a total waste of money, ISCO should trade on it's own credentials, which are very good and getting better quarter over quarter, really looking forward to the 10K, which will start a longer term uptrend IMHO.

GLTA.

A.H

I still see a rally, it took almost 500000 shares thrown into the market in the last half hour to bring it back down to 23, rally still intact IMHO.

GLTA.

A.H

BREAKOUT!!!!!!! and great volume, lets see if 30 cents is tested this time around.

GLTA.

A.H

WOW 170000 shares traded in the first 5 min and the stock is moving up, this looks like the breakout!

GLTA.

A.H

I was actually surprised to see it close red yesterday, looked like it was going to break out under increased volume, lets see if today brings any clues as to the direction of the stock in the near term.

GLTA.

A.H

Couldn't agree more, when compared to it's peers it is very undervalued at a minuscule 22 cents, this year it will move for sure, and I intent on hanging on for the ride, long term with a positive result from the Parkinson trials, the stock should go absolutely crazy.

GLTA.

A.H

Thanks for that, looks like the increases in sales are accelerating, as per your revenue numbers it is 3% then 13,4% and last quarter it was 14,6% if they continue this trend then 4th quarter should come in at just under $2 mil, which is min $ 8 mil per year.

This year could really be the year when ISCO takes off in a big way, I reckon that it will really start getting some attention if they show $2 mil in their annual result.

GLTA.

A.H

Couldn't agree more, and when looking at their last quarter revenue of $1,6 mil, they are currently at $6,4 mil per year going forward with no increases in sales, assuming they can grow sales like they have in the last couple of years, then this year should see min $7-8 mil in sale. Truly undervalued at these prices.

GLTA.

A.H

couldn't agree more, looks really strong here with increased volume as well, not a huge volume but increased at slightly higher prices, on a Friday where the overall market is getting slaughtered shows great strength IMHO.

GLTA.

A.H

Just jumped in with a small position, have been following ISCO on and off for a few years, after it was first mentioned by the Cox, anyways they seem to be getting really close now and the chart looks great.

GLTA.

A.H